SEP 07, 2016 12:00 PM PDT

Community Acquired Bacterial Pneumonia- a 2016 perspective

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Consultant Medical Microbiologist
    Biography
      Glenn Tillotson has 30+ years pharmaceutical experience in early pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. Dr Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and most recently solithromycin. Glenn has held several key committee positions at the American College of Chest Physicians, he is on the Scientific Steering Committee for the GTCBio the Annual Summit on Anti-infective Partnering. Currently Dr Tillotson has published >150 peer-reviewed manuscripts, presented >270 scientific posters and is on several journal Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine Expert Reviews in Anti-Infective Therapy and F1000.

    Abstract:

    Community acquired pneumonia affects over 5 million Americans and 6 million Europeans annually. Typically 5-10% will be admitted to hospital. It is a condition that more often affects the elderly with a commensurately higher mortality rate, which can be as high as 25%. Indeed over 50,000 deaths occur in the USA each year due to this infection. Diagnosis of pneumonia is almost exclusively clinical in terms of signs and symptoms although a positive chest X ray is vital.

    Approximately half of all pneumonia infections are caused by bacteria, the remainder are viral in origin. Streptococcus pneumoniae accounts for the majority of the bacterial cases. As with many other bacterial species the pneumococcus is becoming resistant to many of the commonly used antibiotics. As a result the US FDA has re-assigned the infection to be called Community Acquired Bacterial Pneumonia (CABP).

    Learned guidelines recommend either a macrolide or a doxycycline as the first choices for the low risk patient or a respiratory fluoroquinolone for those at higher risk or who have failed an initial course. Resistance to both first line agents is increasing in the USA   leading to a growing list of adverse consequences such as emergency room visits, hospitalization or re-admission to hospital. This presentation will review the current knowledge of the disease and the challenges of managing these patients.

    Learning Objective 1 : to appreciate the escalating burden of CABP in the USA

    Learning Objective 2 : to understand the impact antibiotic resistance can have in CABP

    Learning Objective 3 : to understand the current challenges in managing CABP
     


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources